The Life Sciences team advised Garuda Therapeutics on its launch and $72 million Series A financing led by Aisling Capital, Northpond Ventures, and OrbiMed, and supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc., and Mass General Brigham Ventures, among others.
Garuda is developing the world’s first platform technology for generating off-the-shelf, self-renewing blood stem cells. The technology is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, the technology could provide potentially curative therapies for more than 70 diseases.
The Goodwin team was led by Michael Bison, Christopher Denn, and Amarilice Young, and included Dan Karelitz (Tax); Sarah Bock and Alexandra Denniston (ERISA & Executive Compensation); Timothy Holahan, Jacob Osborn and Gozde Guckaya (Global Trade); Jacqueline Klosek and Maggie Wong (Opinions); with invaluable assistance from Timothy Ayotte (Corporate), Stephanie Hartford (Summer Associate), and Jackie Serrano (Paralegal).
For more details, read the press release.